...
首页> 外文期刊>Synthetic Metals >Conjugation of methotrexate onto dedoped Fe3O4/PPy nanospheres to produce magnetic targeting drug with controlled drug release and targeting specificity for HeLa cells
【24h】

Conjugation of methotrexate onto dedoped Fe3O4/PPy nanospheres to produce magnetic targeting drug with controlled drug release and targeting specificity for HeLa cells

机译:甲氨蝶呤在去掺杂的Fe3O4 / PPy纳米球上的缀合以产生磁性靶向药物,该药物具有受控的药物释放和对HeLa细胞的靶向特异性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Magnetic composite nanospheres carrying amino groups have attracted much interest due to their potential applications in the fields of catalysis, sensor, water purification, enzyme immobilization, DNA extraction, and drug delivery. In this paper, dedoped Fe3O4/polypyrrole (PPy) nanospheres with core-shell structure, high magnetization, superparamagnetism, and size meeting the demand of biorelated applications in vivo have been achieved by an in situ polymerization approach. The amount of the surface amino groups of Fe3O4/PPy is greatly enhanced by dedoping treatment due to liberation of the amino groups ever sheltered by the dopants, a situation that is responsible for facile conjugation of fluorescein and methotrexate (MIX) onto the magnetic composite through the EDC/NHS coupling chemistry to produce the desirable fluorescent Fe3O4/PPy/MTX targeting drug with a high MTX loading of ca. 109 mu g mg(-1). The as-obtained magnetic targeting drug exhibits controlled drug release, enhanced intracellular drug retention, and specific targeting ability to HeLa cells, presenting a promising candidate for treatment of cancer cells overexpressing folate receptors. (C) 2015 Elsevier B.V. All rights reserved.
机译:带有氨基的磁性复合纳米球因其在催化,传感器,水净化,酶固定,DNA提取和药物递送领域的潜在应用而引起了人们的极大兴趣。在本文中,通过原位聚合方法实现了具有核壳结构,高磁化,超顺磁性和尺寸满足体内生物相关应用需求的掺杂Fe3O4 /聚吡咯(PPy)纳米球。 Fe3O4 / PPy的表面氨基基团的数量由于去掺杂处理的释放而大大增加,这是由于掺杂剂所掩盖的氨基基团的释放所致,这种情况导致荧光素和甲氨蝶呤(MIX)容易通过共轭结合到磁性复合材料上通过EDC / NHS偶联化学反应产生所需的荧光Fe3O4 / PPy / MTX靶向药物,MTX负载量约为10%。 109微克mg(-1)。如此获得的磁性靶向药物表现出受控的药物释放,增强的细胞内药物保留和对HeLa细胞的特异性靶向能力,为治疗过表达叶酸受体的癌细胞提供了有希望的候选者。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号